Want to see IN:HESTERBIO full AI Analyst Report?
Top Page
Hester Biosciences Limited
(HESTERBIO)
Select Model
Select Model
Rating:67Neutral
Price Target:
₹2,322.00
▲(44.61% Upside)
Action:Reiterated
Date:07/14/26
The score is primarily supported by improving financial performance (profitability rebound and better leverage) and strong technical momentum with price above major moving averages. These positives are offset by a demanding valuation (high P/E and low yield) and lingering financial quality risks from historically volatile margins and uneven cash flow.
Positive Factors
Steady Revenue Growth
Sustained revenue expansion indicates continued demand for Hester Biosciences’ veterinary vaccines and animal-health products. The 2026 re-acceleration strengthens the underlying growth profile, supporting investment in distribution, product development, and manufacturing capabilities over the next several quarters.
Negative Factors
Margin Volatility
Historically inconsistent margins make it harder to assess the durability of the latest profitability rebound. Earnings may remain sensitive to product mix, pricing, costs, or operating execution, which could limit the predictability of profits and reduce confidence in near-term earnings quality.
Read all positive and negative factors
Positive Factors
Negative Factors
Steady Revenue Growth
Sustained revenue expansion indicates continued demand for Hester Biosciences’ veterinary vaccines and animal-health products. The 2026 re-acceleration strengthens the underlying growth profile, supporting investment in distribution, product development, and manufacturing capabilities over the next several quarters.
Read all positive factors
Hester Biosciences Limited (HESTERBIO) vs. iShares MSCI India ETF (INDA)
Market Cap
₹18.50B
Dividend Yield0.52%
Average Volume (3M)415.00
Price to Earnings (P/E)13.2
Beta (1Y)0.58
Revenue Growth4.09%
EPS Growth262.23%
CountryIN
Employees483
SectorGeneral
Sector StrengthN/A
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)160.60
Shares Outstanding8,506,865
10 Day Avg. Volume211
30 Day Avg. Volume415
Financial Highlights & Ratios
PEG Ratio0.17
Price to Book (P/B)2.88
Price to Sales (P/S)3.12
P/FCF Ratio24.86
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Hester Biosciences Limited Business Overview & Revenue Model
Company Description
Hester Biosciences Limited, founded in 1987 and headquartered in Ahmedabad, India, specializes in the production and commercialization of veterinary vaccines and a comprehensive array of animal health solutions. The company's operations span both ...
How the Company Makes Money
Hester Biosciences makes money primarily by selling animal healthcare products, with its core revenue stream coming from veterinary vaccines (biologicals) used in poultry and livestock. Revenue is generated through: (1) domestic product sales in I...
Hester Biosciences Limited Financial Statement Overview
Summary
Income Statement
74
Positive
Balance Sheet
66
Positive
Cash Flow
62
Positive
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.26B | 3.33B | 3.11B | 3.05B | 2.66B | 2.35B |
| Gross Profit | 1.85B | 1.69B | 2.08B | 972.64M | 1.89B | 1.66B |
| EBITDA | 1.01B | 866.58M | 649.76M | 582.46M | 619.20M | 731.93M |
| Net Income | 1.36B | 556.39M | 274.88M | 188.89M | 266.27M | 393.20M |
Balance Sheet | ||||||
| Total Assets | 0.00 | 6.78B | 6.53B | 6.62B | 6.70B | 5.62B |
| Cash, Cash Equivalents and Short-Term Investments | 65.38M | 65.38M | 72.19M | 153.04M | 148.17M | 252.20M |
| Total Debt | 0.00 | 1.95B | 2.13B | 2.44B | 2.74B | 2.28B |
| Total Liabilities | -3.68B | 3.10B | 3.27B | 3.59B | 3.81B | 2.95B |
| Stockholders Equity | 3.68B | 3.60B | 3.14B | 2.92B | 2.80B | 2.60B |
Cash Flow | ||||||
| Free Cash Flow | 91.06M | 417.03M | 439.20M | 237.37M | -541.66M | -869.02M |
| Operating Cash Flow | 174.78M | 595.31M | 645.11M | 481.34M | 235.96M | 88.08M |
| Investing Cash Flow | -22.74M | -49.00M | -190.03M | -226.54M | -769.99M | -1.17B |
| Financing Cash Flow | -155.89M | -421.53M | -517.17M | -260.45M | 417.58M | 1.12B |
Hester Biosciences Limited Technical Analysis
Negative
1605.75
Price Trends
2334.95
Negative
2204.15
Negative
1856.56
Positive
Market Momentum
-46.33
Positive
39.73
Neutral
34.69
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:HESTERBIO, the sentiment is Negative. The current price of 1605.75 is below the 20-day moving average (MA) of 2228.31, below the 50-day MA of 2334.95, and below the 200-day MA of 1856.56, indicating a neutral trend. The MACD of -46.33 indicates Positive momentum. The RSI at 39.73 is Neutral, neither overbought nor oversold. The STOCH value of 34.69 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:HESTERBIO.
Hester Biosciences Limited Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | ₹24.01B | 20.67 | ― | 0.56% | 20.87% | 116.29% | |
67 Neutral | ₹18.50B | 13.24 | ― | 0.52% | 4.09% | 262.23% | |
58 Neutral | ₹50.47B | 85.41 | ― | 0.17% | 17.51% | 9.17% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
50 Neutral | ₹7.40B | 168.29 | ― | 0.15% | 7.55% | -57.19% | |
49 Neutral | ₹6.95B | 11.39 | ― | 1.20% | 3.63% | 24.22% | |
46 Neutral | ₹11.02B | 42.60 | ― | 0.35% | -9.58% | ― |
* General Sector Average
IN:HESTERBIO
Hester Biosciences Limited
2,140.60
271.11
14.50%
IN:SIGACHI
Sigachi Industries Limited
28.25
-11.21
-28.41%
IN:VENUSREM
Venus Remedies Limited
1,784.40
1,332.91
295.22%
IN:WANBURY
Wanbury Limited
199.00
-55.00
-21.65%
IN:ZIMLAB
Zim Laboratories Ltd.
136.45
65.09
91.21%
IN:GUJTHEM
Gujarat Themis Biosyn Ltd
382.35
-20.19
-5.02%
Hester Biosciences Limited Corporate Events
Hester Biosciences Posts Strong Q1 FY27 Unaudited Results, Profit Nearly Doubles
Jul 30, 2026
Hester Biosciences Limited’s board has approved the unaudited standalone and consolidated financial results for the quarter ended 30 June 2026, following recommendations from the audit committee. The company will publish an extract of these ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.